Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response. The post Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real